Restless legs is a medical disorder and can be treated

作者
Roger M. Pinder
出处
期刊:Neuropsychiatric Disease and Treatment [Dove Medical Press]
卷期号:2 (4): 391-392 被引量:2
标识
DOI:10.2147/nedt.2006.2.4.391
摘要

Movement disorders have long been an interest of the Editor of Neuropsychiatric Disease and Treatment (Brimblecombe and Pinder 1972). Movement disorders can manifest as slowness or poverty of movement (hypokinesias) or as abnormal involuntary movements (hyperkinesias). Two of the commonest hyperkinesias are essential tremor, which has been described in a previous issue of the journal (Uccellini et al 2006), and restless legs syndrome (RLS), which occupies much of the current issue and was also reviewed in a recent issue (Byrne et al 2006). RLS is a sensorimotor disorder characterized by an irresistible urge to move the limbs accompanied by uncomfortable sensations, leading to disturbed sleep and a poor quality of life. Symptoms usually begin or worsen during periods of rest or inactivity, and are partly or completely relieved by active movement. Symptoms tend to worsen in the evening and at night. Not all cases where legs are restless are due to RLS, and it can be distinguished from nocturnal leg cramps, positional discomfort, and akathisia. However, almost all RLS patients also experience periodic limb movements (PLMs) during sleep or while awake. RLS is a chronic neurological condition that occurs in two forms, a primary disorder independent of other disorders, and a form that is secondary to other conditions such as pregnancy, iron deficiency, and end-stage renal disease. RLS affects about 5%–10% of the general adult population, but the risk increases in the elderly and in women. It can also affect children and adolescents, and is more common in children with ADHD. An early age of onset is indicative of a family history, while the familial nature of RLS is indicated by the demonstration of linkage to several chromosomal loci. The pathogenesis involves dopaminergic dysfunction, iron metabolism, and abnormalities in supraspinal inhibition. Diagnosis is simple and based upon well-validated criteria. Nevertheless, RLS is misunderstood, frequently misdiagnosed, often classified as a psychogenic disorder, and patients can suffer inappropriate treatment and consequent distress. With correct diagnosis, counseling, and reassurance, many patients will not require pharmacological treatment which will be determined by the severity and nature of the symptoms. Treatment of secondary RLS should focus on the underlying cause where possible. Some drugs may exacerbate RLS, including antidepressants particularly tricyclics and fluoxetine, some antiemetics, calcium channel blockers, phenytoin, and excessive consumption of caffeine or alcohol especially at bedtime. Evidence-based treatment guidelines for RLS are available (Byrne et al 2006). Dopaminergic therapies are first-line treatments but there is also substantial, but lesser, evidence for the efficacy of some antiepileptic dugs especially gabapentin, for opioids like oxycodone and propoxyphene, for benzodiazepines particularly clonazepam, and for the α2-adrenergic agonist clonidine. Iron therapy, despite the evidence for the involvement of iron in the causality of RLS, has not been consistently shown to be effective, although it is recommended whenever serum ferritin levels are low. In this issue of Neuropsychiatric Disease and Treatment the biopsychosocial aspects of RLS and particularly mental health problems like disturbances of mood and cognition are reviewed (Becker 2006), as well as the major influence that RLS has on sleep especially when it is accompanied by PLMs (Bogan 2006). Both authors also briefly review treatment options and conclude that the evidence base is strongest for dopaminergic therapies and in particular ropinirole. Disturbed sleep, diminished quality of life, and mood symptoms are all alleviated by therapy with dopamine agonists. Individual dopaminergic agents are also reviewed. Ropinirole is currently the only FDA-approved therapy for RLS, a decision based upon several large scale clinical trials which established its safety and efficacy in treating the motor symptoms of RLS and improving sleep quality (Kushida 2006). Oral pramipexole (Benbir and Guilleminault 2006) and transdermal rotigotine (Bunten and Happe 2006), which are approved in many countries for the treatment of Parkinson’s disease, have also undergone successful large-scale, randomized, and placebo-controlled trials in RLS. Data on pramipexole and rotigotine are promising, and both drugs should be soon added to the armamentarium of treatments for RLS. Other dopaminergic agents useful in RLS include L-dopa itself and the ergot derivatives pergolide and cabergoline (Becker 2006; Bogan 2006). Restless legs is a medical disorder that can be safely and effectively treated.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1ying2ya完成签到,获得积分10
1秒前
xyl_507发布了新的文献求助10
1秒前
柳林风声完成签到,获得积分10
1秒前
酷波er的应助被小宝采纳,获得10
2秒前
柚子呀完成签到,获得积分10
2秒前
zmang完成签到 ,获得积分10
3秒前
samchen完成签到,获得积分10
4秒前
Jasper的应助被稳重的馒头采纳,获得10
5秒前
11kk完成签到,获得积分10
5秒前
谢兰发布了新的文献求助10
5秒前
6秒前
123发布了新的文献求助10
7秒前
7秒前
7秒前
小研完成签到,获得积分10
8秒前
科研眼镜蛇完成签到,获得积分10
8秒前
计划喜欢变化完成签到,获得积分10
8秒前
pan完成签到,获得积分10
8秒前
尉迟莲发布了新的文献求助10
9秒前
9秒前
Edenn完成签到,获得积分10
9秒前
石心粥发布了新的文献求助10
10秒前
10秒前
徐枘发布了新的文献求助10
10秒前
科研通AI65的应助被平常迎天采纳,获得30
11秒前
11秒前
11秒前
苗条梨愁发布了新的文献求助10
12秒前
12秒前
天天快乐的应助被能不学习吗采纳,获得10
12秒前
13秒前
甜甜的饼干完成签到 ,获得积分10
13秒前
14秒前
姚琛发布了新的文献求助10
15秒前
鹤轩发布了新的文献求助10
15秒前
可爱的函函的应助被XZM采纳,获得10
16秒前
DRX发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611